Monash IVF shreds more than share price with second embryo bungle
The collapse in the company’s share price suggests investors think customers will abandon the fertility market leader, too. One way or another, this crisis is likely to lead to change.
It will surely take a minor miracle for Monash IVF to emerge from the crisis engulfing the company in its current form.
Shareholders fled the group’s share register on Tuesday after it revealed it had mistakenly transferred the wrong embryo to a patient, the second such incident this year. Now the company risks an exodus of customers and prospective customers, whose trust in Monash simply must have been badly damaged by the events of the past few months.
Loading...
James Thomson is senior Chanticleer columnist based in Melbourne. He was the Companies editor and editor of BRW Magazine. Connect with James on Twitter. Email James at j.thomson@afr.com
